Developments Intelgenx announced that the FDA has finished its preliminary review and accepted Intelgenx’s NDA filing for CPI-300, a 450mg extended release Bupropion tablet. Impact Positive. Intelgenx is keeping to its timeline and we should see the tablet approved by Q4/09 and on the market by Q1/10. Comments The FDA has begun its full review of Intelgenx’s 450mg Bupropion tablet, which is excellent news for the company and maintains their timeline.